Vivani Medical, Inc. (VANI)
Automate Your Wheel Strategy on VANI
With Tiblio's Option Bot, you can configure your own wheel strategy including VANI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VANI
- Rev/Share 0.0034
- Book/Share 0.1962
- PB 6.6758
- Debt/Equity 1.6294
- CurrentRatio 2.3955
- ROIC -0.8182
- MktCap 77609509.0
- FreeCF/Share -0.3683
- PFCF -3.5575
- PE -3.2675
- Debt/Assets 0.5342
- DivYield 0
- ROE -1.3307
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
Read More
Vivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists' (AAPS) “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop, taking place from May 13-14, 2025.
Read More
Vivani Medical Announces $8.25M Private Placement Equity Financing
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of $1.12 per share, expected to result in gross proceeds of approximately $8.25 million in a private placement.
Read More
What Makes Vivani Medical (VANI) a New Buy Stock
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Vivani Medical, Inc. (VANI)
- IPO Date 2014-11-19
- Website https://www.vivani.com
- Industry Medical - Devices
- CEO Adam Mendelsohn
- Employees 37